DaVita Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/16/2026)
| Balance Sheet | Total Assets | 17,480,103,000.00 | ROE | -3.72 % |
| Balance Sheet | Total Equity | -651,082,000.00 | ROA | 4.27 % |
| Cashflow | Capital Expenditures | -575,864,000.00 | P/FCF | 12.15 |
| Cashflow | Free Cash Flow | 1,310,636,032.00 | – | – |
| Cashflow | Operating Cash Flow | 1,886,500,000.00 | P/CF | 8.44 |
| Income | Earnings per Share (diluted) | 8.48 | Div. Yield | – |
| Income | Net Income | 746,803,000.00 | P/E | 21.31 |
| Income | Shares Outstanding | 68,549,000.00 | P/B | -24.45 |
| Income | Total Revenue | 13,643,069,000.00 | P/S | 1.17 |
Ratios calculated on: 10/14/2026
Company Description
DaVita HealthCare Partners Inc., formerly DaVita Inc., is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2011, the Company provided dialysis and administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving a total of approximately 142,000 patients. It also provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services throughout the United States. In July 2013, DaVita, a division of DaVita HealthCare Partners Inc announced the acquisition of the dialysis operations of Malaysia's Caring Dialysis Centre Group (CDC Group) by DVA (Malaysia) Sdn Bhd.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.davita.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more